MAY 14, 2015 1:30 PM PDT

Germline Cancer Genetics in 2015

Speaker
  • Director, Center for Cancer Genetics and Prevention, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute
    Biography
      Dr. Garber received her MD and MPH in 1981 from Yale University School of Medicine. She served her internal medicine residency at Brigham and Women's Hospital, followed by fellowships in hematology at BWH, medical oncology at DFCI, and biostatistics at the National Cancer Institute. She joined DFCI as a fellow in 1985, and now works as a medical oncologist and clinical cancer geneticist.
      <br />
      <br />

    Abstract

    Germline cancer genetics became a reality with the cloning of the tumor suppressor gene RB1 for hereditary retinoblastoma in 1986 by Friend and Weinberg. The existence of cancer susceptibility genes had been predicted by Knudson and Strong in the so-called "two-hit" hypothesis that was developed based on observations that there were families in which cancers clustered and occurred at younger ages, more often bilaterally in paired organs or as multiple primary tumors, and far more frequently than they did otherwise in the general population. In 2015 there have been hundreds of cancer susceptibility genes identified. Most code for proteins that are involved in DNA repair or other regulatory processes rather than structural proteins. In classical cancer genetics, individuals with cancer or with a family history of the disease may seek evaluation for the possible presence of a cancer predisposition syndrome. If the gene for that syndrome is known, blood or saliva from a family member most likely to carry a predisposing mutation is submitted for analysis to one of the commercial labs. The best candidate in the family would have had a tumor that is a component of the syndrome diagnosed at an early age, for example. Molecular analysis of the germline can be focused on candidate genes (e.g. MMR genes for Lynch syndrome, PTEN for Cowden's syndrome) or performed as part of a panel of cancer susceptibility genes by NGS now available from a number of commercial laboratories. However, incidental identification of germline mutations may now occur in the process of molecular analysis of tumors performed in order to identify therapeutic targets, in the course of which a mutation in a gene that can confer hereditary predisposition may be found. Separate testing of germline material would be indicated to determine whether or not the identified mutation was acquired, and therefore somatic, or germline, which could have implications not only for the patient but also for the family. For some types of cancer, the presence of an underlying hereditary predisposition can affect treatment recommendations or surveillance for additional primary cancers in survivors as well as family members (BRCA1/2 mutations in hereditary breast or ovarian cancer, TP53 mutations in Li Fraumeni Syndrome and radiation oncogenesis, With current whole exome and whole genome analyses being offered to adults and in the prenatal setting, incidental identification of germline mutations in cancer predisposition genes as incidental findings have been part of discussions by genetics and ethicists. Mutations identified in dominant cancer susceptibility genes are on the list of those that should be disclosed in the statement by the American College of Medical Genetics, though there remains some controversy around this issue.


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    Loading Comments...
    Show Resources
    Attendees